著論文: 症例報告を含む）
Arashiro T,Arima Y,Muraoka H,Sato A,Oba K,Uehara Y,Arioka H,Yanai H,Kuramochi J,Ihara G,Chubachi K,Yanagisawa N,Nagura Y,Kato Y,Ueda A,Numata A,Kato H,Ishii K,Ooki T,Oka H,Nishida Y,Stucky A,Smith C,Hibberd M,Ariyoshi K,Suzuki M. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection during Delta-dominant and Omicron-dominant periods in Japan: a multi-center prospective case-control study (FASCINATE study). Clin Infect Dis. 2022:ciac635.
Arashiro T,Arima Y,Muraoka H,Sato A,Oba K,Uehara Y,Arioka H,Yanai H,Yanagisawa N,Nagura Y,Kato Y,Kato H,Ueda A,Ishii K,Ooki T,Oka H,Nishida Y,Stucky A,Miyahara R,Smith C,Hibberd M,Ariyoshi K,Suzuki M. Behavioral factors associated with SARS-CoV-2 infection in Japan. Influenza Other Respir Viruses. 2022;16(5):952-961.
Doi Y,Ishihara T,Banno S,Ando M,Kondo M; Favipiravir Observational Study. Favipiravir for symptomatic COVID-19: A nationwide observational cohort study. J Infect Chemother. 2023;29(2):150-156.
Ide K,Asami T,Suda A,Yoshimi A,Fujita J,Shiraishi Y,Nomoto M,Miyauchi M,Roppongi T,Furuno T,Watanabe K,Shimada T,Kaneko T,Saigusa Y,Kubota K,Kato H,Odawara T,Hishimoto A. The psychological distress and suicide-related ideation in hospital workers during the COVID-19 pandemic: Second results from repeated cross-sectional surveys. PLoS One. 2022;17(11):e0277174.
Kanai D,Wakui H,Haze T,Azushima K,Kinguchi S,Kanaoka T,Toya Y,Hirawa N,Kato H,Uneda K,Watanabe F,Hanaoka K,Hanaoka M,Mitsuhashi H,Yamaguchi S,Ohnishi T,Tamura K. Improved immune response to the third COVID-19 mRNA vaccine dose in hemodialysis patients. Kidney Int Rep. 2022;7(12):2718-2721.
Kato H,Okamoto R,Miyoshi S,Noguchi S,Umeda M,Chiba Y. Expansion of droplets during speaking and singing in Japanese. PLoS One. 2022;17(8):e0272122.
Kato H,Miyakawa K,Ohtake N,Yamaoka Y,Yajima S,Yamazaki E,Shimada T,Goto A,Nakajima H,Ryo A. Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination. Vaccine. 2022;40(19):2652-2655.
Kazuaki Obata,Kei Miyakawa,Toshiki Takei,Atsuhiko Wada,Yasuyoshi,Hatayama,Hideaki Kato,Yayoi Kimura,Hisakuni Sekino,Junichi Katada, Akihide Ryo. Prospective clinical evaluation of the diagnostic accuracy of a highly sensitive rapid antigen test using silver amplification technology for emerging SARS-CoV-2 variants. Biomedicines. 2022;10(11):2801.
Miyakawa K,Kato H (co-first),Ohtake N,Stanleyraj Jeremiah S,Ryo A. Enhancement of humoral and cellular immunity against SARS-CoV-2 by a third dose of BNT162b2 vaccine in Japanese healthcare workers. J Infect Dis. 2022:jiac344.
Miyakawa K,Jeremiah SS,Yamaoka Y,Koyama T,Tokumasu R,Kudo M,Kato H,Ryo A. Molecular and epidemiological characterization of emerging immune-escape variants of SARS-CoV-2. Front Med (Lausanne). 2022;9:811004.
Miyake S,Kato H,Tanaka N,Shimizu K,Ozawa H,Kawakami C,Usuku S,Nakajima H,Yamamoto T. Ideal Test Time for Coronavirus Disease 2019 Contact Tracing. Front Public Health. 2022;9:690006.
Morioka H,Ohge H,Nagao M,Kato H,Kokado R,Yamada K,Yamada T,Shimono N,Nukui Y,Yoshihara S,Sakamaki I,Nosaka K,Kubo Y,Kawamura H,Fujikura Y,Kitaura T,Sunakawa M,Yagi T; Research Group of Japan Infection Prevention and Control Conference for National and Public University Hospitals. Appropriateness of surgical antimicrobial prophylaxis in Japanese university hospitals. J Hosp Infect. 2022:S0195-6701(22)00218-3.
Ogawa F,Oi Y,Honzawa H,Misawa N,Takeda T,Kikuchi Y,Fukui R,Tanaka K,Kano D,Kato H,Abe T,Takeuchi I. Severity predictors of COVID-19 in SARS-CoV-2 variant,delta and omicron period; single center study. PLoS One. 2022;17(10):e0273134.
Ohishi T,Yamagishi T,Kurosu H,Kato H,Takayama Y,Anan H,Kunishima H. SARS-CoV-2 Delta AY.1 Variant Cluster in an Accommodation Facility for COVID-19: Cluster Report. Int J Environ Res Public Health. 2022;19(15):9270.
Ohno Y,Aoyagi K,Arakita K,Doi Y,Kondo M,Banno S,Kasahara K,Ogawa T,Kato H,Hase R,Kashizaki F,Nishi K,Kamio T,Mitamura K,Ikeda N,Nakagawa A,Fujisawa Y,Taniguchi A,Ikeda H,Hattori H,Murayama K,Toyama H. Newly developed artificial intelligence algorithm for COVID-19 pneumonia: utility of quantitative CT texture analysis for prediction of favipiravir treatment effect. Jpn J Radiol. 2022;40(8):800-813.
Oka K,Matsumoto A,Tetsuka N,Morioka H,Iguchi M,Ishiguro N,Nagamori T,Takahashi S,Saito N,Tokuda K,Igari H,Fujikura Y,Kato H,Kanai S,Kusama F,Iwasaki H,Furuhashi K,Baba H,Nagao M,Nakanishi M,Kasahara K,Kakeya H,Chikumi H,Ohge H,Azuma M,Tauchi H,Shimono N,Hamada Y,Takajo I,Nakata H,Kawamura H,Fujita J; Japan Infection Prevention and Control Conference for National and Public University Hospitals. Clinical characteristics and treatment outcomes of carbapenem-resistant Enterobacterales infections in Japan. J Glob Antimicrob Resist. 2022:S2213-7165(22)00082-0.
++Samukawa S,Yoshimi R,Kojitani N,Uzawa Y,Takase-Minegishi K,Kirino Y,Soejima Y,Kato H,Nakajima H.:Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report. Journal of Infection and Chemotherapy,29(3),347-352,2022
Yamaoka Y,Jeremiah SS,Funabashi R,Miyakawa K,Morita T,Mihana Y,Kato H,Ryo A. Characterization and Utilization of Disulfide-Bonded SARS-CoV-2 Receptor Binding Domain of Spike Protein Synthesized by Wheat Germ Cell-Free Production System. Viruses. 2022;14(7):1461.
Yamayoshi S,Iwatsuki-Horimoto K,Okuda M,Ujie M,Yasuhara A,Murakami J,Duong C,Hamabata T,Ito M,Chiba S,Kobayashi R,Takahashi S,Mitamura K,Hagihara M,Shibata A,Uwamino Y,Hasegawa N,Ebina T,Izumi A,Kato H,Nakajima H,Sugaya N,Seki Y,Iqbal A,Kamimaki I,Yamazaki M,Kawaoka Y,Furuse Y. Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era,Japan,February 2020-March 2022. Emerg Infect Dis. 2022;28(11):2198-2205.
加藤英明．AID（DI）の倫理—出自を知る権利をめぐるこれまでの議論の経過と今後の課題—「子どもの立場から考えるDI（AID）の出自を知る権利」出自を知る権利をめぐるこれまでの議論と経緯と今後の課題The Ethics of Donor Insemination: History and Future on the Right to Know One’s Origin．医学哲学医学倫理．2022;40:61–65.
